Levetiracetam Alters Oscillatory Connectivity in Alzheimer's Disease.

  title={Levetiracetam Alters Oscillatory Connectivity in Alzheimer's Disease.},
  author={Christian Sand{\o}e Musaeus and Mouhsin M. Shafi and Emiliano Santarnecchi and Susan T. Herman and Daniel Z. Press},
  journal={Journal of Alzheimer's disease : JAD},
  volume={58 4},
Seizures occur at a higher frequency in people with Alzheimer's disease (AD) but overt, clinically obvious events are infrequent. Evidence from animal models and studies in mild cognitive impairment suggest that subclinical epileptic discharges may play a role in the clinical and pathophysiological manifestations of AD. In this feasibility study, the neurophysiological and cognitive effects of acute administration of levetiracetam (LEV) are measured in patients with mild AD to test whether it… 

Figures and Tables from this paper

Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.

A phase 2a randomized double-blinded placebo-controlled crossover clinical trial of 34 adults with AD found levetiracetam was well tolerated and, although it did not improve the primary outcome, in prespecified analysis, levetIRacetam improved performance on spatial memory and executive function tasks in patients with AD and epileptiform activity.

Temporal Lobe Epilepsy and Alzheimer’s Disease: From Preclinical to Clinical Evidence of a Strong Association

A review of evidence linking epileptiform activity, network hyperexcitability, and AD, and their role promoting and accelerating neurodegenerative process is provided.

Sleep: The Tip of the Iceberg in the Bidirectional Link Between Alzheimer's Disease and Epilepsy

The literature was scrutinized for mechanisms that might promote sleep-related epileptic activity in AD and, possibly dementia onset in epilepsy, and to what degree and through which processes such events might alter the progression of AD.

Neurophysiological signatures in Alzheimer’s disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline

Frequency-specific neurophysiological signatures of AD pathophysiology are demonstrated and MEGI is suggested to be sensitive indices of network disruptions mediated by TAU and Aβ and associated cognitive decline and facilitate the pursuit of novel therapeutic approaches toward normalizing network synchrony in AD.

Neuronal Network Excitability in Alzheimer’s Disease: The Puzzle of Similar versus Divergent Roles of Amyloid β and Tau

Characteristics of neuronal network excitability in AD, and the role of Aβ and tau in the induction of network hyperexcitability are discussed.

Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core study

Significant sex differences in pharmacokinetics of levetiracetam were observed in 5XFAD mice, highlighting the importance of PK/PD relationships in preclinical studies to inform clinical study design.

Inhibiting Epileptiform Activity in Cognitive Disorders: Possibilities for a Novel Therapeutic Approach

The aim of this review is to describe the data on the prevalence of epileptiform activity in various cognitive disorders, to summarize the current knowledge of the mechanisms of epileptic activity in relation to cognitive impairment, and to explore the utility of antiepileptic drugs in the therapy of cognitive disorders.

Electroencephalogram Based Biomarkers for Detection of Alzheimer’s Disease

Electroencephalogram (EEG)-based biomarkers may be used as a first-line decision-support tool in AD diagnosis and could complement other AD biomarkers.



Effect of levetiracetam monotherapy on background EEG activity and cognition in drug-naïve epilepsy patients

Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model

The hypothesis that aberrant network activity contributes causally to synaptic and cognitive deficits in hAPP mice is supported and levetiracetam might also help ameliorate related abnormalities in people who have or are at risk for AD.

Changes in background electroencephalography and regional cerebral glucose metabolism in focal epilepsy patients after 1-month administration of levetiracetam

The antiseizure efficacy and safety of levetiracetam (LEV) is well documented; however, few clinical studies have investigated the predictability of patient responsiveness to LEV, especially when the

Levetiracetam: A Practical Option for Seizure Management in Elderly Patients With Cognitive Impairment

Cognitive impairment and seizures are common in elderly individuals with cognitive impairment and anticonvulsant treatment is problematic due to sedation, cognitive slowing, and behavioral changes; levetiracetam has favorable pharmacokinetics, good efficacy, and a favorable side effect profile.

Epilepsy and cognitive impairments in Alzheimer disease.

It is concluded that beta-amyloid peptides may contribute to cognitive decline in AD by eliciting similar aberrant neuronal activity in humans and discuss potential clinical and therapeutic implications of this hypothesis.

EEG coherence in Alzheimer's disease.

Effect of levetiracetam in patients with epilepsy and interictal epileptiform discharges

Doses of levetiracetam of up to 2000 mg/day were well tolerated, and no interactions were seen with concomitant AEDs.

A longitudinal EEG study of mild senile dementia of Alzheimer type: changes at 1 year and at 2.5 years.